532 related articles for article (PubMed ID: 17823933)
1. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
3. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
Huynh H; Nguyen TH; Panasci L; Do P
Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed.
Hara T; Omura-Minamisawa M; Kang Y; Cheng C; Inoue T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1485-95. PubMed ID: 18640498
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
7. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
Mohiuddin M; Chendil D; Dey S; Alcock RA; Regine W; Mohiuddin M; Ahmed MM
Anticancer Res; 2002; 22(2A):825-30. PubMed ID: 12014658
[TBL] [Abstract][Full Text] [Related]
8. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
[TBL] [Abstract][Full Text] [Related]
9. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Bartussek C; Naumann U; Weller M
Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
[TBL] [Abstract][Full Text] [Related]
11. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines.
Dey S; Spring PM; Arnold S; Valentino J; Chendil D; Regine WF; Mohiuddin M; Ahmed MM
Clin Cancer Res; 2003 Apr; 9(4):1557-65. PubMed ID: 12684432
[TBL] [Abstract][Full Text] [Related]
12. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
13. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Parker LP; Wolf JK; Price JE
Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
[TBL] [Abstract][Full Text] [Related]
14. Enhanced radiosensitization of p53 mutant cells by oleamide.
Lee YJ; Chung DY; Lee SJ; Ja Jhon G; Lee YS
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1466-74. PubMed ID: 16580498
[TBL] [Abstract][Full Text] [Related]
15. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.
Takei Y; Kadomatsu K; Goto T; Muramatsu T
Cancer; 2006 Aug; 107(4):864-73. PubMed ID: 16832814
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer.
Eiseman JL; Rogers FA; Guo Y; Kauffman J; Sentz DL; Klinger MF; Callery PS; Kyprianou N
Cancer Res; 1998 Nov; 58(21):4864-70. PubMed ID: 9809992
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
18. Low-dose irradiation and short-exposure suboptimal-dose paclitaxel adversely modulate metastatic potential of squamous carcinoma cells.
Lövey J; Fazekas K; Ladányi A; Németh G; Tímár J
Strahlenther Onkol; 2003 Dec; 179(12):812-8. PubMed ID: 14652669
[TBL] [Abstract][Full Text] [Related]
19. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
King TC; Estalilla OC; Safran H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535
[TBL] [Abstract][Full Text] [Related]
20. Expression of Nkx3.1 enhances 17beta-estradiol anti-tumor action in PC3 human prostate cancer cells.
Wang P; Liu B; Luo JD; Zhang ZG; Ma Q; Chen ZD
Asian J Androl; 2007 May; 9(3):353-60. PubMed ID: 17486276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
